Extending the Promise of Immunotherapy to Pancreatic Cancer

Video

In Partnership With:

Stephanie K. Dougan, PhD, assistant professor, microbiology and immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways to extend the promise of immunotherapy to the field of pancreatic cancer.

Stephanie K. Dougan, PhD, assistant professor, microbiology and immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways to extend the promise of immunotherapy to the field of pancreatic cancer.

Patients with pancreatic cancer have a very poor prognosis overall, explains Dougan. The disease becomes metastatic very quickly, which has translated to a 5-year survival rate of under 10%. The current standard of care is combination chemotherapy—–either gemcitabine and paclitaxel or FOLFIRINOX. However, neither of these regimens translate to a significant extension in survival, says Dougan.

Research has turned toward immunotherapy as a way to improve survival for patients. Notably, in December 2018, the combination of the CXCR4 antagonist BL-8040 and the PD-1 inhibitor pembrolizumab (Keytruda) showed encouraging survival data in a phase IIa trial of patients with metastatic pancreatic adenocarcinoma (NCT02826486). Data reported at the 2018 ESMO Congress revealed a median overall survival of 3.4 months, and 7.5 months for those who had received at least 1 prior line of therapy.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD